** Cancer therapy developer Zymeworks' ZYME.O shares up as much as 10.6% to $13.91
** Brokerage J.P.Morgan upgrades company's shares to "overweight" from "neutral", raises PT by $6 to $18
** Recent R&D day event has brokerage more confident in company's oncology and autoimmune diseases pipeline, with two distinct TCE, ADC cancer therapies progressing in the clinics - JPM
** Company's cancer drug Zani provides "solid support" to stock valuation - brokerage
** JPM believes 2025 is the year to pay attention and could begin to see one or more of company's "5x5" pipeline plan succeeding in clinics
** Zymeworks' internal portfolio is largely underappreciated at this level as it begins to take shape as a true "multiple shots on goal" story with attractive upside potential - brokerage
** Brokerage Jefferies also raises PT on company's shares by $2 to $24
** 6 of 8 brokerages rate the stock "buy" or higher, and 2 "hold"; median PT $18.75 - LSEG
** Including session moves, stock up 32% YTD
(Reporting by Neil J Kanatt in Bengaluru)
((Neil.JKanatt@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。